Research Article
Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients
Table 1
Demographic data and clinical measures.
| Parameter | ESRD and HCV | HCV+ | ESRD | HC |
| Gender | Men | 18 | 9 | 13 | 12 | Women | 22 | 11 | 7 | 8 | Age (years ± SE) | 55.2 ± 1.47 | 53.8 ± 2.32 | 55.6 ± 2.84 | 52.9 ± 1.67 | Dialysis (years ± SE) | 13.8 ± 1.26 | — | 3.85 ± 0.34 | — | HCV status (years ± SE) | 7.02 ± 0.67 | 8.25 ± 1.04 | — | — |
|
|
(Mann–Whitney test).
|